Preclinical development of the quadrivalent meningococcal (ACYW) tetanus toxoid conjugate vaccine, MenQuadfi®
Sign Up to like & getrecommendations! Published in 2022 at "Glycoconjugate Journal"
DOI: 10.1007/s10719-022-10050-2
Abstract: Bacterial capsular polysaccharide vaccines are generally poorly immunogenic in infants and older adults. The immunogenicity of capsular polysaccharide vaccines can be improved by conjugating them to immunogenic carrier proteins. One of the most recently licensed… read more here.
Keywords: tetanus toxoid; development; conjugate; conjugate vaccine ... See more keywords
Persistence of bactericidal antibodies 4 years after a booster dose of quadrivalent meningococcal diphtheria toxoid conjugate vaccine (MenACWY-D).
Sign Up to like & getrecommendations! Published in 2019 at "Vaccine"
DOI: 10.1016/j.vaccine.2019.01.008
Abstract: One dose of quadrivalent meningococcal conjugate vaccine (MenACWY) was first recommended for US adolescents (ages 11-12 years) in 2005 to protect against invasive meningococcal disease (IMD). In 2010, after evidence emerged about waning protection within 5 years… read more here.
Keywords: vaccine menacwy; quadrivalent meningococcal; conjugate vaccine; vaccine ... See more keywords
Safety of quadrivalent meningococcal conjugate vaccine in infants and toddlers 2 to 23-months old.
Sign Up to like & getrecommendations! Published in 2019 at "Vaccine"
DOI: 10.1016/j.vaccine.2019.10.024
Abstract: INTRODUCTION The quadrivalent meningococcal conjugate vaccine MenACWY-CRM is recommended for 2-23 month-old infants/toddlers at increased risk for meningococcal disease. This study adds to the current knowledge of MenACWY-CRM safety among this age group in a clinical… read more here.
Keywords: infants toddlers; safety; quadrivalent meningococcal; vaccine ... See more keywords